Literature DB >> 17327330

Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.

José Manuel Fernández-Real1, José María Moreno, Berta Chico, Abel López-Bermejo, Wifredo Ricart.   

Abstract

OBJECTIVE: Visfatin is a novel adipokine that is predominantly secreted by visceral adipose tissue. Accumulation of visceral adipose tissue is also associated with iron metabolism. Despite the coincidence of visfatin expression in iron-rich tissues, no study has investigated the possible interaction of visfatin with parameters of iron metabolism. RESEARCH DESIGN AND METHODS: We evaluated insulin sensitivity and parameters of iron metabolism in 95 men with normal glucose tolerance (NGT) and 43 men with altered glucose tolerance.
RESULTS: Men with newly diagnosed type 2 diabetes had significantly increased serum visfatin in parallel with increased serum prohepcidin and serum ferritin compared with the other groups. In all subjects as a whole, circulating visfatin was not found to be significantly linked to insulin sensitivity (r = 0.07, P = 0.4) but was significantly associated with serum prohepcidin concentration (r = 0.40, P < 0.0001). Obesity status and glucose tolerance status influenced the relationships among visfatin, insulin sensitivity, and parameters of iron metabolism. Among men with altered glucose tolerance, serum visfatin was strongly associated with serum prohepcidin (r = 0.61, P < 0.0001) and serum soluble transferrin receptor (sTfR) (r = -0.51, P < 0.0001). In nonobese subjects, sTfR (P = 0.02) and prohepcidin (P = 0.04) contributed independently to visfatin variance after controlling for age and BMI. When insulin sensitivity was added to the model, only the latter (P = 0.006) contributed to 17% of visfatin variance. In obese men, however, only sTfR (P = 0.04) contributed independently to visfatin variance in this latter model.
CONCLUSIONS: Serum visfatin concentration is significantly associated with parameters of iron metabolism, especially in subjects with altered glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327330     DOI: 10.2337/dc06-1581

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  15 in total

1.  Nicotinamide Phosphoribosyltransferase in Human Diseases.

Authors:  Li Qin Zhang; Daniel P Heruth; Shui Qing Ye
Journal:  J Bioanal Biomed       Date:  2011-01-07

Review 2.  Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver.

Authors:  Elmar Aigner; Günter Weiss; Christian Datz
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Iron and diabetes risk.

Authors:  Judith A Simcox; Donald A McClain
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

4.  Circulating ferritin concentrations are differentially associated with serum adipokine concentrations in Japanese men and premenopausal women.

Authors:  Yasumi Kimura; Kazuki Yasuda; Kayo Kurotani; Shamima Akter; Ikuko Kashino; Hitomi Hayabuchi; Masao Sato; Tetsuya Mizoue
Journal:  Eur J Nutr       Date:  2016-08-02       Impact factor: 5.614

5.  Fasting serum levels of ferritin are associated with impaired pancreatic beta cell function and decreased insulin sensitivity: a population-based study.

Authors:  Linéa Bonfils; Christina Ellervik; Nele Friedrich; Allan Linneberg; Camilla H Sandholt; Marit E Jørgensen; Torben Jørgensen; Torben Hansen; Oluf Pedersen; Kristine H Allin
Journal:  Diabetologia       Date:  2014-12-14       Impact factor: 10.122

6.  Maternal visfatin concentration in normal pregnancy.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

7.  The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery.

Authors:  José I Botella-Carretero; Manuel Luque-Ramírez; Francisco Alvarez-Blasco; Roberto Peromingo; José L San Millán; Héctor F Escobar-Morreale
Journal:  Obes Surg       Date:  2008-03-19       Impact factor: 4.129

8.  Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

9.  Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Chia-Lang Nhan-Chang; Neil Hamill; Edi Vaisbuch; Tinnakorn Chaiworapongsa; Samuel S Edwin; Jyh Kae Nien; Ricardo Gomez; Jimmy Espinoza; Claire Kendal-Wright; Sonia S Hassan; Gillian Bryant-Greenwood
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.